Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

EXACT Sciences Corporation

Healthcare US EXAS

103.37USD
-0.34(0.33%)

Last update at 2026-03-10T20:09:00Z

Day Range

103.33103.69
LowHigh

52 Week Range

46.77100.77
LowHigh

Fundamentals

  • Previous Close 103.71
  • Market Cap8676.60M
  • Volume2607909
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-108.44300M
  • Revenue TTM2534.84M
  • Revenue Per Share TTM14.00
  • Gross Profit TTM 1509.88M
  • Diluted EPS TTM-1.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -632.57000M -842.50600M -857.10500M -268.85100M -175.05700M
Minority interest - - - - -
Net income -623.50600M -595.62500M -848.53300M -83.99300M -175.14900M
Selling general administrative 737.30M 801.26M 481.72M 352.45M 178.29M
Selling and marketing expenses 846.01M 861.89M 589.92M 385.18M 249.45M
Gross profit 1509.88M 1308.33M 1137.07M 659.58M 336.48M
Reconciled depreciation 197.56M 180.35M 163.36M 50.25M 23.08M
Ebit -577.54200M -835.46800M -558.35300M -233.78200M -182.55500M
Ebitda -480.09200M -740.46700M -464.95500M -217.74700M -159.47100M
Depreciation and amortization 97.45M 95.00M 93.40M 16.04M 23.08M
Non operating income net other -19.42500M 31.78M 6.90M 26.53M 21.20M
Operating income -577.54200M -835.46800M -558.35300M -233.78200M -159.47100M
Other operating expenses 2661.82M 2602.55M 2049.74M 1110.08M 613.93M
Interest expense 19.63M 18.61M 95.98M 61.60M 36.79M
Tax provision -9.06400M -246.88100M -8.57200M -184.85800M 0.09M
Interest income - - - 24.47M 15.59M
Net interest income -19.63400M -18.60600M -88.02900M -61.59900M -36.78900M
Extraordinary items - - - - -
Non recurring 15.97M 20.21M 209.67M - -
Other items - - - - -
Income tax expense -9.06400M -246.88100M -8.57200M -184.85800M 0.09M
Total revenue 2084.28M 1767.09M 1491.39M 876.29M 454.46M
Total operating expenses 2087.43M 2143.80M 1695.42M 893.36M 495.95M
Cost of revenue 574.39M 458.76M 354.32M 216.72M 117.98M
Total other income expense net -55.02800M -7.03800M -298.75200M -35.06900M 21.20M
Discontinued operations - - - - -
Net income from continuing ops -623.50600M -595.62500M -848.53300M -83.99300M -175.14900M
Net income applicable to common shares -623.50600M -595.62500M -848.53300M -83.99300M -175.14900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6471.33M 6226.87M 6684.88M 4925.09M 3505.77M
Intangible assets 1890.40M 1956.24M 2094.41M 848.43M 1143.55M
Earning assets - - - - -
Other current assets 85.63M 73.90M 74.12M 33.16M 40.91M
Total liab 3326.03M 3183.71M 3297.25M 2101.60M 1217.71M
Total stockholder equity 3145.30M 3043.16M 3387.64M 2823.49M 2288.06M
Deferred long term liab - - - - -
Other current liab 14.82M 309.46M 30.97M 38.27M 8.47M
Common stock 1.81M 1.78M 1.74M 1.59M 1.48M
Capital stock 1.81M 1.78M 1.74M 1.59M 1.48M
Retained earnings -3469.17500M -3265.02600M -2641.52000M -1968.28900M -1119.75600M
Other liab - 345.06M 417.78M 61.58M 28.11M
Good will 2367.12M 2346.04M 2335.17M 1237.67M 1203.20M
Other assets - 36.68M 74.59M 63.77M 20.29M
Cash 605.38M 242.49M 315.47M 1491.29M 177.25M
Cash and equivalents - - - - -
Total current liabilities 514.70M 412.75M 517.07M 575.84M 236.49M
Current deferred revenue 341.68M - 398.56M 233.60M 193.33M
Net debt 1949.35M 2204.38M 2046.93M -27.11100M 769.05M
Short term debt 79.38M 28.37M 19.71M 268.27M 8.72M
Short long term debt 50.00M - - 256.78M 0.83M
Short long term debt total 2554.72M 2446.87M 2362.40M 1464.18M 946.30M
Other stockholder equity 6611.24M 6311.64M 6028.86M 4789.66M 3406.44M
Property plant equipment - 684.76M 754.47M 450.68M 455.32M
Total current assets 1194.37M 982.26M 1426.24M 2198.59M 556.96M
Long term investments - - - - -
Net tangible assets - 697.12M -1041.94700M 737.39M -58.68600M
Short term investments 172.27M 389.56M 715.00M 348.70M 146.40M
Net receivables 203.62M 158.04M 216.65M 233.19M 130.67M
Long term debt 2314.28M 2186.11M 2180.23M 1343.10M 827.64M
Inventory 127.47M 118.26M 104.99M 92.27M 61.72M
Accounts payable 78.82M 74.92M 67.83M 35.71M 25.97M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.43M -5.23600M -1.44300M 0.53M -0.10000M
Additional paid in capital - - - - -
Common stock total equity - 1.78M 1.74M 1.59M 1.48M
Preferred stock total equity - - - - -
Retained earnings total equity - -3265.02600M -2641.52000M -1968.28900M -1119.75600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -287.54600M 90.58M 74.59M 63.77M 20.29M
Deferred long term asset charges - - - - -
Non current assets total 5276.97M 5244.62M 5258.65M 2726.50M 2948.81M
Capital lease obligations 190.45M 210.76M 201.88M 132.56M 126.56M
Long term debt total - 2186.11M - - 827.64M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 49.68M 278.76M -387.77200M -219.22500M 1026.44M
Change to liabilities - -52.18000M 169.80M 55.16M 3.47M
Total cashflows from investing activities - 74.07M -1082.08500M -702.03700M -121.07300M
Net borrowings - 50.00M -23.74900M 975.49M 236.44M
Total cash from financing activities 159.77M 76.48M 8.47M 1879.62M 253.18M
Change to operating activities - -22.05400M -74.62000M 32.94M -10.04600M
Net income -204.14900M -623.50600M -595.62500M -848.53300M -83.99300M
Change in cash 366.88M -72.97800M -1175.82600M 1314.07M 17.10M
Begin period cash flow 242.79M 315.77M 1491.59M 177.53M 160.43M
End period cash flow 609.67M 242.79M 315.77M 1491.59M 177.53M
Total cash from operating activities 156.12M -223.55900M -102.23600M 136.48M -115.01000M
Issuance of capital stock - 0.00000M 0.00000M 861.70M 0.00000M
Depreciation 206.61M 197.56M 180.35M 163.36M 50.25M
Other cashflows from investing activities - 9.77M -0.74400M -418.46000M -975.71300M
Dividends paid 169.52M - 37.51M 18.36M 17.18M
Change to inventory -7.69000M -13.23100M -9.22100M -30.31000M -19.04100M
Change to account receivables -43.41600M 61.09M 25.15M -100.52600M -27.93800M
Sale purchase of stock 28.34M 25.49M 23.07M 18.36M 8.40M
Other cashflows from financing activities 21.79M 44.47M 9.15M 1167.97M 738.14M
Change to netincome - 181.28M 195.25M 777.61M 106.52M
Capital expenditures 124.19M 214.46M 135.77M 64.35M 171.80M
Change receivables - 61.09M 25.15M -100.52600M -27.93800M
Cash flows other operating - 118.41M -129.54900M 113.20M -152.32000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -73.00800M -1175.84900M 1314.07M 17.10M
Change in working capital -0.34200M -26.37700M 111.11M -42.72900M -53.55600M
Stock based compensation 231.31M 206.82M 253.06M 152.91M 108.48M
Other non cash items -76.35500M 33.84M 202.04M 721.34M 48.92M
Free cash flow 31.93M -438.02100M -238.00200M 72.13M -286.81200M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EXAS
EXACT Sciences Corporation		 -0.34 0.33% 103.37 - - 5.18 4.12 5.89 503.12
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXACT Sciences Corporation

5505 Endeavor Lane, Madison, WI, United States, 53719

Key Executives

Name Title Year Born
Mr. Kevin T. Conroy Chairman of The Board & CEO 1966
Mr. Jeffrey T. Elliott CFA Exec. VP, CFO & COO 1978
Mr. D. Scott Coward Chief Legal Officer 1965
Mr. Graham P. Lidgard Emeritus Chief Science Officer 1949
Mr. Everett V. Cunningham Chief Commercial Officer 1966
Dr. Jorge A. Garces Ph.D. Chief Science Officer 1972
Mr. Sri Kalluri Chief Information Officer NA
Ms. Megan Jones Associate Mang. of Investor Relations NA
Mr. Tim Caprez Chief Compliance Counsel & VP NA
Mr. Vic Parker Head of Sales NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.